207 related articles for article (PubMed ID: 31808843)
1. Opportunities for immunotherapy in childhood acute myeloid leukemia.
Lamble AJ; Tasian SK
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):218-225. PubMed ID: 31808843
[TBL] [Abstract][Full Text] [Related]
2. Opportunities for immunotherapy in childhood acute myeloid leukemia.
Lamble AJ; Tasian SK
Blood Adv; 2019 Nov; 3(22):3750-3758. PubMed ID: 31770440
[TBL] [Abstract][Full Text] [Related]
3. The future of cellular immunotherapy for childhood leukemia.
Bonifant CL; Tasian SK
Curr Opin Pediatr; 2020 Feb; 32(1):13-25. PubMed ID: 31851053
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
5. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
7. Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.
Davila J; Slotkin E; Renaud T
Paediatr Drugs; 2014 Apr; 16(2):151-68. PubMed ID: 24158739
[TBL] [Abstract][Full Text] [Related]
8. Advances in immunotherapy for pediatric acute myeloid leukemia.
Bonifant CL; Velasquez MP; Gottschalk S
Expert Opin Biol Ther; 2018 Jan; 18(1):51-63. PubMed ID: 28945115
[TBL] [Abstract][Full Text] [Related]
9. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
10. Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation.
Rettinger E; Willasch AM; Kreyenberg H; Borkhardt A; Holter W; Kremens B; Strahm B; Woessmann W; Mauz-Koerholz C; Gruhn B; Burdach S; Albert MH; Schlegel PG; Klingebiel T; Bader P
Blood; 2011 Nov; 118(20):5681-8. PubMed ID: 21948300
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
[TBL] [Abstract][Full Text] [Related]
12. Improved outcome of childhood acute myeloid leukemia in an Eastern European country: Lithuanian experience.
Kairiene I; Pasauliene R; Lipunova N; Vaitkeviciene G; Rageliene L; Rascon J
Eur J Pediatr; 2017 Oct; 176(10):1329-1337. PubMed ID: 28812191
[TBL] [Abstract][Full Text] [Related]
13. Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation.
Gesundheit B; Shapira MY; Resnick IB; Amar A; Kristt D; Dray L; Budowski E; Or R
Am J Hematol; 2009 Mar; 84(3):188-90. PubMed ID: 19105234
[TBL] [Abstract][Full Text] [Related]
14. [Allogenic transplantation of hematopoietic stem cells in the treatment of children with high-risk acute leukemia].
Starý J; Kobylka P; Sedlácek P; Komrska V; Vávra V; Syrůcková Z; Smísek P; Hrubá A; Korínková P; Matĕjková E; Cukrová V; Dolezalová L; Loudová M; Sejkorová J; Kvĕch J
Cas Lek Cesk; 1998 Jun; 137(12):363-7. PubMed ID: 9721472
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem cell transplantation for children with acute myeloid leukemia in second remission: A report from the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group.
Selim A; Alvaro F; Cole CH; Fraser CJ; Mechinaud F; O'Brien TA; Shaw PJ; Tapp H; Teague L; Nivison-Smith I; Moore AS
Pediatr Blood Cancer; 2019 Aug; 66(8):e27812. PubMed ID: 31111633
[TBL] [Abstract][Full Text] [Related]
16. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.
Snauwaert S; Vanhee S; Goetgeluk G; Verstichel G; Van Caeneghem Y; Velghe I; Philippé J; Berneman ZN; Plum J; Taghon T; Leclercq G; Thielemans K; Kerre T; Vandekerckhove B
Haematologica; 2012 Oct; 97(10):1539-47. PubMed ID: 22532518
[TBL] [Abstract][Full Text] [Related]
17. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of T cells transduced with a chimeric antigen receptor to treat relapsed or refractory acute leukemia: efficacy and feasibility of immunotherapy approaches.
Ding G; Chen H
Sci China Life Sci; 2016 Jul; 59(7):673-7. PubMed ID: 27142351
[TBL] [Abstract][Full Text] [Related]
19. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
[TBL] [Abstract][Full Text] [Related]
20. Early versus late preemptive allogeneic hematopoietic cell transplantation for relapsed or refractory acute myeloid leukemia.
Chen GL; Liu H; Zhang Y; Thomas J; Ross M; Wang ES; Block AW; Sait S; Deeb G; Wallace P; Wetzler M; Hahn T; McCarthy PL
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1369-74. PubMed ID: 24867777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
